Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Peakman

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
F1000 Biology Reports|November 1, 2012
Can we vaccinate against Type 1 diabetes?Mark Peakman
Clinical and Experimental Immunology|June 26, 2008
Notice of redundant publicationMark Peakman
Novartis Foundation Symposium|February 11, 2009
CD8 and cytotoxic T cells in type 1 diabetesMark Peakman
Diabetologia|May 26, 2017
Antigen-specific immunotherapy and influenza vaccination in type 1 diabetes: timing is everythingLorraine Yeo, Mark Peakman
Cold Spring Harbor Perspectives in Medicine|September 16, 2024
Autoantigen-Specific Immunotherapies for the Prevention and Treatment of Type 1 DiabetesMark Peakman, Pere Santamaria
Diabetes/Metabolism Research and Reviews|December 4, 2003
Enteroviruses and type 1 diabetesRuben Varela-Calvino, Mark Peakman
Nature Immunology|May 21, 2008
The habitual, diverse and surmountable obstacles to human immunology researchAdrian C Hayday, Mark Peakman
Diabetes|September 1, 2010
Antigen-specific immunotherapy for type 1 diabetes: maximizing the potentialMark Peakman, Matthias von Herrath
Nature Reviews. Immunology|January 26, 2010
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetesBart O Roep, Mark Peakman
Frontiers in Immunology|March 16, 2018
Peptide Immunotherapy for Type 1 Diabetes-Clinical AdvancesEmma L Smith, Mark Peakman
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
F1000 Biology Reports|November 1, 2012
Can we vaccinate against Type 1 diabetes?Mark Peakman
Clinical and Experimental Immunology|June 26, 2008
Notice of redundant publicationMark Peakman
Novartis Foundation Symposium|February 11, 2009
CD8 and cytotoxic T cells in type 1 diabetesMark Peakman
Diabetologia|May 26, 2017
Antigen-specific immunotherapy and influenza vaccination in type 1 diabetes: timing is everythingLorraine Yeo, Mark Peakman
Cold Spring Harbor Perspectives in Medicine|September 16, 2024
Autoantigen-Specific Immunotherapies for the Prevention and Treatment of Type 1 DiabetesMark Peakman, Pere Santamaria
Diabetes/Metabolism Research and Reviews|December 4, 2003
Enteroviruses and type 1 diabetesRuben Varela-Calvino, Mark Peakman
Nature Immunology|May 21, 2008
The habitual, diverse and surmountable obstacles to human immunology researchAdrian C Hayday, Mark Peakman
Diabetes|September 1, 2010
Antigen-specific immunotherapy for type 1 diabetes: maximizing the potentialMark Peakman, Matthias von Herrath
Nature Reviews. Immunology|January 26, 2010
Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetesBart O Roep, Mark Peakman
Frontiers in Immunology|March 16, 2018
Peptide Immunotherapy for Type 1 Diabetes-Clinical AdvancesEmma L Smith, Mark Peakman
Pageof 15